Biocon Chief Sees Bright Future For Indian Pharma In Trump Era

Biocon’s chair and managing director, Kiran Mazumdar-Shaw, tells Scrip she sees a strong partnering role for Indian firms in the Trump regime, but adds that “carte blanche” pricing that innovator companies enjoyed could come under check.

Kiran Mazumdar-Shaw

More from Business

More from Scrip